longevity

Life Biosciences has dosed its first patient with ER-100, a cellular rejuvenation therapy aiming to reverse age-related sight loss, in a first-ever human clinical trial approved by the FDA.

This newsletter covers David Sinclair's plan to test whole-body rejuvenation drugs in the XPrize competition, key AI trends from a talk at SXSW London, and OpenAI's confidential IPO filing.

David Sinclair plans to test an oral epigenetic reprogramming drug, SL-100, in the XPrize competition for whole-body rejuvenation, aiming for a 10-year age reversal.

New Limit's cellular reprogramming therapy, delivered via mRNA in lipid nanoparticles, restores liver resilience and improves survival in aged mice subjected to repeated alcohol cycles, with human trials planned next year in Australia.

Brian Armstrong announces that NewLimit has developed a prototype drug that reverses cellular aging in human cells, with a clinical trial scheduled for next year, and has raised $435M in Series C funding led by Founders Fund.

The article examines growing skepticism about the scientific validity of blue zones, the longevity hotspots popularized by Dan Buettner, as researchers question the data and commercialization of the concept.

Dr. Derya Unutmaz suggests humanity may be approaching longevity escape velocity, where each year lived could grant over one extra year of life, potentially saving millions if achieved sooner.

A report details Russian President Vladimir Putin's $26 billion national effort to advance antiaging research, encompassing technologies like organ printing, cryotherapy, and genetics.

MIT Technology Review's newsletter covers three major stories: Anthropic's Code with Claude event showing developers increasingly shipping AI-written code without review, the upcoming Enhanced Games for athletes using performance-enhancing drugs, and Google I/O's shift towards agentic AI for science with Gemini for Science.

The inaugural Enhanced Games, where athletes are encouraged to use performance-enhancing drugs, reflects societal trends toward human enhancement and longevity in 2026. The event offers substantial prizes and raises questions about safety and ethics.

OpenAI collaborated with Retro Biosciences to develop GPT-4b micro, a specialized version of GPT-4o for protein engineering, achieving 50-fold higher expression of stem cell reprogramming markers with enhanced DNA damage repair capabilities. The findings have been validated across multiple donors and cell types, demonstrating AI's potential to accelerate life sciences research.

Josh Woodward, head of Google Labs, sits down with cardiologist Dr. Eric Topol to discuss how AI can give time back to doctors, restore the doctor-patient relationship, and shift medicine from reactive treatment to proactive prevention. They also cover Topol's daily use of NotebookLM and the key findings from "Super Agers."